PDX Models Market Projected Worth $ 275.58 million by 2025 | Companies are Crown Bioscience, Charles River, Champion Oncology, Jackson Laboratory, Oncodesign, Aragen Bioscience, MI Bioresearch, EUROPDX, Creative Animodel, Urolead, Xentech, Hera BioLabs

This report gives an understanding on all the most recent advancements, item dispatches, joint wanders, mergers and acquisitions by the a few key players and brands of the PDX Models advertise. It contains the summation of showcase definition, classifications, and advertise patterns of the Healthcare IT industry and PDX models market. The estimate period is anticipated to be exceptionally solid for the PDX models market and the Healthcare IT industry as well.

The report moreover outlines the CAGR values for the noteworthy a long time 2016, the base year 2017 and the estimate for the long time 2018-2025. The company profiles of all the imperative players in North America, Europe, Japan, China, India, Southeast Asia and other districts (Central & South America, and the Center East & Africa) are examined with the assistance of SWOT investigation and Porter’s Five Powers tool.

Looking for more information on this market? Get Free sample report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-pdx-models-market

PDX models are better than traditional cell line xenograft models because they resembles to the tumors found in actual patients. For example, a detailed cytogenetic analysis of PDX models revealed strong preservation of the chromosomal architecture observed in patients. According to statistics published by the World Health Organization (WHO), cancer accounts for 13.0% deaths every year worldwide resulting in 8.2 million deaths approximately.

Global PDX Models Market Analysis By

By Type (Mice Models, Rat Models),

By Tumor Type (Respiratory Tumor Models, Urological Tumor Models, Gastrointestinal Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Others)

By Application (Preclinical Drug Development & Oncology Research, Biomarker Analysis)

By End User (Contract Research Organization, Academic & Research Institutions, Pharmaceutical & Biotechnology Companies)

By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Drivers: Global PDX Models Market

Prominent factors driving the growth of this market consist of rising number of pharmaceutical R&D activities in cancer research, advantages offered by PDX models offer compared with the classic approach, rising need for personalized medicine and increasing support for cancer research activities from government and non-government organization.

RISING NUMBER OF PHARMACEUTICAL R&D ACTIVITIES IN CANCER RESEARCH

Cancer is the second most death causing disease in people around the world. According to the study by WHO, there were almost 8.8 million deaths noted due to the cancer in the year 2015 globally. In low- and middle-income countries, 70.0% of deaths are due to cancer. Due to rising cancer prevalence worldwide, the healthcare sector and organizations (both public and private) are investing huge amount of money to carry out various scientific researches to develop novel drugs and technology to treat disease. Government bodies across are investing heavily in research activities for advancements in the field of cancer across the globe. Biotech and pharma companies are accelerating drug development activities in the oncology sector. According to the International Federation of Pharmaceutical Manufacturers & Associations key facts 2017, pharmaceutical industry currently spends over USD 149.8 Billion on R&D activities per year.

Looking for more insights from this report? click the link below @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-pdx-models-market

Patient Derived Xenograft (PDX) models are majorly used by pharmaceutical and biotechnology companies as models for oncology research. These models provide various aspects of genesis, progression, and clinical course of human cancers. PDX models are generated by transplanting fresh human tumor specimen from a cancer patient into a mouse or rat. Therefore, these models give near accurate assessment of human tumor biology, identification of therapeutic targets, preclinical screening, and evaluation of drugs for various cancers.

According to the article published by THE JACKSON LABORATORY, cancer research is going to get help in improving data sharing and reproducibility. This will be possible through the new minimal information standard for Patient Derived Xenograft (PDX) models, which will make the models easy to find, access, integrate and reuse which are highly used in research.

THE JACKSON LABORATORY is also spending in R&D programs. In 2017, they tripled their investments from previous year. Below mentioned are the investment stats for the amount spent by the company for new research and development.

In 2017, Oncodesign (France), which is a biopharma company dedicated to the precision medicine, invested around 16.15 million USD in 2017 for the research and development activities, which was almost double investment from the previous year.

PDX MODELS OFFER ADVANTAGES AS COMPARED WITH THE CLASSIC APPROACH

The PDX models offer several numbers of benefits and advantages as compared to the conventional xenografts approaches.

According to an article published by the MI Bioresearch Inc., in March 2017, in a study nine out of ten that is almost 90.0% attempts were failed trying to brought a new oncology therapy to the clinics. These preclinical data and clinical results were obtained by using the traditional approach. The article revealed that there is very low success rate with the traditional approaches.

The traditional approach shows that there are drugs, which quickly fail in the clinical trials. In last 10 years there were 9,985 new drugs entering Phase I clinical trials with 31.2% (3,163) for oncology indications alone. There were high failure rates which lead to industry disapproval. The traditional preclinical animal models have limited abilities to carry out researches and often give extremely inaccurate results.

Questions? We’ll Put You On The Right Path Request Analyst Call @ https://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-pdx-models-market

Before the PDX model, murine models or traditional cell line models were used to evaluate novel and conventional therapeutic strategies for cancer. There are many other traditional approaches for the cancer diagnosis, which are not as compatible as PDX models. The major disadvantage of using traditional approach is inaccuracy of results. Like, some cancer types such as prostate cancer are very poorly represented as cancer cell lines. There are relatively small numbers available as cancer cell lines, even for those cancer classes that are represented and others. Whereas, there are several benefits of PDX mouse models that are not possibly with traditional approach.

Some of the benefits are given below:

It is a simple subcutaneous engrafting technique (applied under the skin).
It provides improved predictability of treatment outcomes and prognosis.
The potential applications in personalized precision medical treatments.
It also permits direct engraftment of human tumor cells.
It gives easy access to the subcutaneous tumor for biopsy.

Market Players:

• Crown Bioscience Inc,
• WuXi AppTec,
• Champion Oncology, Inc.,
• THE JACKSON LABORATORY,

Some of the major players operating in the market are Oncodesign, Charles River, EPO Berlin-Buch GmbH, Shanghai LIDE, Xentech, Horizon Discovery Group plc, Urolead, Explora BioLabs, Bioduro, Pharmatest Services Ltd, Hera BioLabs, Xenopat, among others.

Some major points from table of content:

1. Introduction
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Market Dynamics
7. Market Segmentation
8. Company Profiles & Competitive Landscape
9. Future of the Market

Browse Detailed TOC, Tables and Figures @ http://databridgemarketresearch.com/toc/?dbmr=global-pdx-models-market

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Sopan Gedam
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.